-
Laminin (925-933): From ECM Signal to Assay Strategy
2026-08-25
Laminin (925-933) is more than a compact adhesion ligand: it is a defined way to separate laminin-receptor signaling from the architectural complexity of full extracellular matrices. This article connects its adhesion and chemotaxis evidence with collagen-VI-enriched iPSC islet organoid research, outlining practical controls, translational opportunities, and the limits of extending peptide data into engineered tissue systems.
-
Sodium Dicloxacillin Monohydrate: Assay Strategy
2026-08-25
Sodium dicloxacillin monohydrate is more than a conventional MSSA antibiotic control: it is a tool for separating compartment, exposure, and endpoint effects in infection research. This guide converts intra- and extracellular pharmacodynamic evidence into a practical assay-design framework.
-
Fangchinoline Restores TFEB Antiviral Lysosomal Defense
2026-08-24
The reference study identifies fangchinoline as a lysosome-targeted inhibitor of H1N1 infection that restores TFEB-dependent lysosomal gene expression, alters lysosomal pH, and obstructs viral entry. Its combined Connectivity Map, transcriptomic, imaging, and functional infection analyses provide a host-directed framework for studying influenza control through lysosomal biology.
-
HyperFusion High-Fidelity DNA Polymerase
2026-08-24
HyperFusion high-fidelity DNA polymerase is a proofreading DNA polymerase designed for accurate, fast PCR amplification of difficult templates. Its product specifications support research workflows involving GC-rich sequences, long amplicons, cloning, and high-throughput sequencing preparation.
-
Sulfo-NHS-SS-Biotin Protocol and QC Guide
2026-08-23
Sulfo-NHS-SS-Biotin enables water-compatible, cleavable labeling of accessible primary amines on proteins and intact cell surfaces for detection, affinity capture, and protein purification. It should not be used for targets lacking accessible amines or as a stored solution because its sulfo-NHS ester hydrolyzes rapidly after dissolution.
-
Angiotensin II, Ferroptosis, and NPC Radioresistance
2026-08-22
This study identifies a local angiotensin II–AGT–HIF-1α–HILPDA circuit that suppresses radiation-induced ferroptosis and promotes radioresistance in nasopharyngeal carcinoma. Its combination of mechanistic molecular assays, ferroptosis phenotyping, radiosensitivity testing, xenograft experiments, and tissue biomarker analysis provides a useful framework for linking tumor hypoxia, lipid metabolism, and radiotherapy response.
-
Azilsartan: From AT1 Blockade to Causal Assays
2026-08-22
Azilsartan (TAK-536) is a selective AT1 receptor probe for dissecting renin-angiotensin signaling in cardiovascular and neuroinflammation research. This article develops an evidence-centered assay framework based on astrocyte–microglia experiments, emphasizing causal interpretation, controls, and translational limitations.
-
Rapamycin, Ferroptosis, and Translational mTOR Strategy
2026-08-21
A translational framework for using Rapamycin (Sirolimus) to interrogate mTOR-regulated metabolism, mitochondrial stress, and adipose stem cell ferroptosis while distinguishing mechanistic evidence from testable hypothesis.
-
MCIP-BiTE Therapy for High-Grade Glioma
2026-08-20
The reference preprint proposes migratory cortical inhibitory interneuron precursors as cellular delivery vehicles for a locally secreted EGFR–CD3 bispecific T-cell engager. In mouse high-grade glioma models, these engineered cells homed toward tumors and extended survival, while also highlighting important translational questions about tumor heterogeneity, cell manufacturing, safety, and immune engagement.
-
Small-Molecule Activation of Human ClpP in Cancer
2026-08-20
The 2025 Future Medicinal Chemistry review explains how small molecules can either activate or inhibit human mitochondrial ClpP, with emphasis on structure–activity relationships, pharmacology, and anticancer development. Its discussion of ZK53 illustrates how selective ClpP hyperactivation can produce mitochondrial electron transport chain disruption, oxidative phosphorylation inhibition, cell-cycle arrest, and ferroptosis sensitization in preclinical models.
-
SW033291: From PGE2 Control to Regeneration
2026-08-19
SW033291 is a potent 15-PGDH inhibitor for studying prostaglandin E2 elevation, hematopoiesis, and tissue repair. This article connects enzyme kinetics with the latest muscle-regeneration findings and shows how to design more discriminating cross-domain assays.
-
Cefotaxime for Resistance and Infection Models
2026-08-19
Cefotaxime is a third-generation cephalosporin antibiotic that can serve as a mechanistic probe in antimicrobial resistance research. This guide connects plasmid-mediated carbapenemase findings with assay design, controls, storage, and interpretation in bacterial infection models.
-
SW033291: 15-PGDH Inhibitor Workflows
2026-08-18
SW033291 is a mechanistically defined 15-PGDH inhibitor for connecting prostaglandin E2 elevation with cell-based regeneration and hematopoietic readouts. This guide translates enzyme, bone marrow, and muscle-repair findings into practical workflows, controls, formulation choices, and troubleshooting steps.
-
SMPD4, Ceramide, and Primary Cilia in Brain Development
2026-08-18
A 2024 Development study connects SMPD4-dependent ceramide production with neural progenitor survival, Purkinje cell development, and primary cilium maintenance. By combining mouse genetics with SMPD4-deficient human iPSC-derived neural cells and ceramide rescue, the work provides a mechanistic framework for SMPD4-associated microcephaly and cerebellar hypoplasia.
-
SAR405 for Reliable Vps34 and Autophagy Assays
2026-08-17
Learn how SAR405 (SKU A8883) helps researchers separate Vps34-dependent autophagy effects from nonspecific viability changes. This scenario-based guide covers assay compatibility, formulation, storage, interpretation, and practical product-selection criteria.